High-target haemodiafiltration convective dose achieved in the majority of patients in a 6-month intermediary analysis of the CONVINCE randomised controlled trial.

IntroductionHigh convection volumes in haemodiafiltration (HDF) result improved survival, however, it remains unclear whether is achievable all patients.MethodsCONVINCE, a randomised controlled trial, patients with end-stage kidney disease 1:1 to high-dose HDF versus high-flux haemodialysis continuation. We evaluated the proportion of achieving target: volume per visit ≥23 L (range ±1 L), at baseline, month 3, and 6. compared baseline characteristics two ways: 1) on target for three visits who missed ≥1 visits; 2) or missing once ≥2 visits.Results653 were HDF. Their mean age was 62.2 (SD 13.5) years, 36% female, 81% had fistula vascular access, 33% diabetic. Across visits, 75 (11%), 27 (4%), 11 (2%) once, twice, times, respectively. Apart from diabetes, there no apparent differences patient between always achieved (83%) those either more (17%), twice (6%).ConclusionAchieving feasible nearly CONVINCE could be maintained during 6-month follow-up period. diabetes other indications confounding by indication multivariable analyses that may explain potential survival advantage receiving